Acquired resistance to hormone therapy is a serious challenge in the treatment of estrogen receptor-positive breast cancers. This most often occurs as a result of mutations in the ESR1 gene. Detecting such variants in cell-free DNA (cfDNA) plasma samples can help researchers understand breast cancer progression, develop better approaches to therapy selection, and improve disease monitoring.
Download this article to learn how the latest ultra-sensitive Droplet Digital PCR ESR1 Mutation Detection Kit helps researchers detect ESR1 mutations for research testing of cfDNA from breast cancer patients for pre-clinical and clinical study applications.
